The Asia-Pacific companion diagnostics market is evaluated to record a CAGR of 13.55% during the projected years of 2022 to 2030, capturing a revenue share of $3584.06 million by 2030.

ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET FORECAST 2022-2030

Asia-Pacific Companion Diagnostics Market by Technology (in Situ Hybridization, Polymerase Chain Reaction, Immunohistochemistry, Next Generation Sequencing, Other Technologies) Market by Indication (Oncology, Neurology, Infectious Diseases, Other Indications) Market by End-user (Pharmaceutical and Biopharmaceutical Companies, Reference Laboratories, Other End-users) Market by Products & Services (Assay Kits and Reagents, Software & Services) by Geography

Request free sample

The Asia-Pacific companion diagnostics market is evaluated to record a CAGR of 13.55% during the projected years of 2022 to 2030, capturing a revenue share of $3584.06 million by 2030.

The tremendous growth in precision medicine technology, collaborations between regulatory authorities, diagnostic companies, the pharmaceutical industry, and service providers to offer an international platform, and the rise in healthcare awareness are among the key drivers credited to the market growth of the region. However, differing regulatory processes between nations for targeted therapies and companion diagnostics may pose a threat to the Asia-Pacific companion diagnostics market growth.

Asia-Pacific Companion Diagnostics Market

To know more about this report, request a free sample copy

The Asia-Pacific companion diagnostics market growth analysis entails the evaluation of China, Australia & New Zealand, South Korea, Indonesia, Singapore, India, Japan, and Rest of Asia-Pacific. China has positioned itself as one of the major contributors to the global in-vitro diagnostics (IVD) market over the last five years. This rapid growth was further boosted by the adoption of IVD in the avenue of cancer diagnostics. Although cancer diagnoses are not widely adopted by developing nations across the Asia-Pacific, access to a significant patient population in urban markets, as well as research competency in genome sequencing, has garnered notable opportunities for international players in the companion diagnostics market.

Moreover, advancing expertise in developing affordable sequencers results in lucrative market prospects for domestic vendors in China, as well. In this regard, companies like Simcere Diagnostics and Shuwen Biotech are among the key contributors to the growth of China’s companion diagnostics market.

Conversely, the Ministry of Health, Labor, and Welfare (MHLW), as well as the Pharmaceutical Medical Devices Agency (PMDA) in Japan, are the key core regulatory authorities handling the country’s medical devices and pharmaceutical products, including IVDs. Japan is also aiming to increase the adoption of companion diagnostics in the country. In this regard, the MHLW issued guidelines for companion diagnostics’ approval and reimbursement, aligning with the Food and Drug Administration’s (FDA) regulatory outline. As a result, these factors are anticipated to proliferate the market growth in the Asia-Pacific over the forecast period.

The Asia-Pacific companion diagnostics market is segmented into technology, indication, products & services, and end-user. The products & services segment includes assay kits and reagents as well as software and services. The assay kits and reagents segment entails the adoption of chemical substances and compounds in procedures associated with companion diagnostic tests. They are utilized to qualitatively investigate, analyze, detect, and assess different types of proteins in human tissue for facilitating the use of targeted drugs.

On the other hand, the software and service segment includes the adoption of various software and service types, such as analytical and clinical validation, biomarker development, companion diagnostic manufacturing, and post-launch support in companion diagnostics technologies. These comprise next-generation sequencing, polymerase chain reaction, and others.

Some of the major players operating in the Asia-Pacific companion diagnostics market are Sysmex Corporation, Amoy Diagnostics, ICarbonX, etc.

Sysmex Corporation, headquartered in Japan, along with its subsidiaries, manufacture, design, sell, and export/import diagnostic devices, reagents, as well as related software for use in urinalysis, hematology, clinical chemistry, immunochemistry, and hemostasis. The company also offers systems for high-volume testing in labs, five-part and three-part white blood cell differentiation equipment for hematology applications, and hematology analyzers for animals.

Report Synopsis

Report ScopeDetails
Market Forecast Years2022-2030
Base Year2021
Market Historical Years2018-2021
Forecast UnitsRevenue ($ Million)
Segments AnalyzedTechnology, Indication, Products & Services, End-User
Countries AnalyzedChina, Australia & New Zealand, South Korea, Indonesia, Singapore, India, Japan, and Rest of Asia-Pacific
Companies Analyzed

Abbott Laboratories, Almac Group, Arup Laboratories, Biocartis, Biomerieux SA, Danaher Corporation, GE Healthcare, Genomic Health, Illumina Inc, Qiagen NV, Agilent, Roche Diagnostics, Sysmex Corporation, Thermo Fisher Scientific Inc

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • KEY DRIVERS
        • GROWING NUMBER OF CANCER CASES AND MORTALITIES
        • INCREASING POPULARITY OF PRECISION MEDICINES
        • RISING NUMBER OF ADVERSE DRUG REACTION CASES
      • KEY RESTRAINTS
        • COUNTRY-SPECIFIC REIMBURSEMENT ISSUES
        • FREQUENT CASES OF LEAKAGE IN COMPANION DIAGNOSTICS FOR ONCOLOGY
    1. KEY ANALYTICS
      • IMPACT OF COVID-19 ON COMPANION DIAGNOSTICS MARKET
      • KEY MARKET TRENDS
      • PORTER’S FIVE FORCES ANALYSIS
        • BUYERS POWER
        • SUPPLIERS POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • VALUE CHAIN ANALYSIS
      • KEY BUYING CRITERIA
      • REGULATORY FRAMEWORK
    2. MARKET BY TECHNOLOGY
      • IN SITU HYBRIDIZATION
      • POLYMERASE CHAIN REACTION
      • IMMUNOHISTOCHEMISTRY
      • NEXT GENERATION SEQUENCING
      • OTHER TECHNOLOGIES
    3. MARKET BY INDICATION
      • ONCOLOGY
      • NEUROLOGY
      • INFECTIOUS DISEASES
      • OTHER INDICATIONS
    4. MARKET BY END-USER
      • PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
      • REFERENCE LABORATORIES
      • OTHER END-USERS
    5. MARKET BY PRODUCTS & SERVICES
      • ASSAY KITS AND REAGENTS
      • SOFTWARE & SERVICES
    6. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • CHINA
          • JAPAN
          • INDIA
          • SOUTH KOREA
          • INDONESIA
          • SINGAPORE
          • AUSTRALIA & NEW ZEALAND
          • REST OF ASIA-PACIFIC
    1. COMPETITIVE LANDSCAPE
      • KEY STRATEGIC DEVELOPMENTS
        • MERGERS & ACQUISITIONS
        • PRODUCT LAUNCHES & DEVELOPMENTS
        • PARTNERSHIPS & AGREEMENTS
      • COMPANY PROFILES
        • ABBOTT LABORATORIES
        • AGILENT
        • ALAMC GROUP
        • ARUP LABORATORIES
        • BIOCARTIS
        • BIOMERIEUX SA
        • DANAHER CORPORATION
        • GE HEALTHCARE
        • GENOMIC HEALTH
        • ILLUMINA INC
        • MYRIAD GENETICS INC
        • QIAGEN NV
        • ROCHE DIAGNOSTICS
        • SYSMEX CORPORATION
        • THERMO FISHER SCIENTIFIC INC

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – COMPANION DIAGNOSTICS

    TABLE 2: NEW CASES OF CANCER PATIENTS IN 2020

    TABLE 3: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 4: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 5: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 6: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 7: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 8: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 9: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 10: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 11: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 12: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 13: LEADING PLAYERS OPERATING IN ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET

    TABLE 14: LIST OF MERGERS & ACQUISITIONS

    TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

    TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS          

    LIST OF FIGURES

    FIGURE 1: CDX LEAKAGE

    FIGURE 2: KEY MARKET TRENDS

    FIGURE 3: PORTER’S FIVE FORCES ANALYSIS

    FIGURE 4: OPPORTUNITY MATRIX

    FIGURE 5: VENDOR LANDSCAPE

    FIGURE 6: VALUE CHAIN ANALYSIS

    FIGURE 7: FDA GUIDELINES FOR CDX APPROVAL

    FIGURE 8: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021

    FIGURE 9: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY IN SITU HYBRIDIZATION, 2022-2030 (IN $ MILLION)

    FIGURE 10: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2030 (IN $ MILLION)

    FIGURE 11: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2030 (IN $ MILLION)

    FIGURE 12: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2030 (IN $ MILLION)

    FIGURE 13: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)

    FIGURE 14: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY INDICATION, IN 2021

    FIGURE 15: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2030 (IN $ MILLION)

    FIGURE 16: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2030 (IN $ MILLION)

    FIGURE 17: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2030 (IN $ MILLION)

    FIGURE 18: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATIONS, 2022-2030 (IN $ MILLION)

    FIGURE 19: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

    FIGURE 20: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)

    FIGURE 21: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2030 (IN $ MILLION)

    FIGURE 22: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)

    FIGURE 23: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY PRODUCTS & SERVICES, IN 2021

    FIGURE 24: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2030 (IN $ MILLION)

    FIGURE 25: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY SOFTWARE & SERVICES, 2022-2030 (IN $ MILLION)

    FIGURE 26: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

    FIGURE 27: CHINA COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 28: JAPAN COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 29: INDIA COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 30: SOUTH KOREA COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 31: INDONESIA COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 32: THAILAND COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 33: AUSTRALIA & NEW ZEALAND COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 34: REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)       

    1. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • CHINA
          • JAPAN
          • INDIA
          • SOUTH KOREA
          • INDONESIA
          • SINGAPORE
          • AUSTRALIA & NEW ZEALAND
          • REST OF ASIA-PACIFIC
    1. MARKET BY TECHNOLOGY
      • IN SITU HYBRIDIZATION
      • POLYMERASE CHAIN REACTION
      • IMMUNOHISTOCHEMISTRY
      • NEXT GENERATION SEQUENCING
      • OTHER TECHNOLOGIES
    2. MARKET BY INDICATION
      • ONCOLOGY
      • NEUROLOGY
      • INFECTIOUS DISEASES
      • OTHER INDICATIONS
    3. MARKET BY END-USER
      • PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
      • REFERENCE LABORATORIES
      • OTHER END-USERS
    4. MARKET BY PRODUCTS & SERVICES
      • ASSAY KITS AND REAGENTS
      • SOFTWARE & SERVICES

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type